Phenotypes associated with this allele

• Allele Symbol: Epn2^tm1Ocr
• Allele Name: targeted mutation 1, Ottavio Cremona
• Allele ID: MGI:4356016
• Summary: 7 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Epn2^tm1Ocr/Epn2^tm1Ocr	B6.129X1-Epn2^tm1Ocr	MGI:4356018
cn2	Epn1^tm1.1Wami/Epn1^tm1.1Wami Epn2^tm1Ocr/Epn2^tm1Ocr Tg(Cdh5-cre/ERT2)CIVE23Mlia/0 Tg(TRAMP)8247Ng/0	involves: 129X1/SvJ * C57BL/6 * C57BL/6J	MGI:5477818
cn3	Epn1^tm1.1Wami/Epn1^tm1.1Wami Epn2^tm1Ocr/Epn2^tm1Ocr Tg(Cdh5-cre/ERT2)CIVE23Mlia/0	involves: 129X1/SvJ * C57BL/6J	MGI:5477817
cn4	Epn1^tm1.1Wami/Epn1^tm1.1Wami Epn2^tm1Ocr/Epn2^tm1Ocr Tg(Cdh5-cre)7Mlia/0	involves: C57BL/6J * FVB/N	MGI:5477819
cx5	Epn1^tm1Ocr/Epn1^+ Epn2^tm1Ocr/Epn2^tm1Ocr	B6.129X1-Epn1^tm1Ocr Epn2^tm1Ocr	MGI:4356020
cx6	Epn1^tm1Ocr/Epn1^tm1Ocr Epn2^tm1Ocr/Epn2^+	B6.129X1-Epn1^tm1Ocr Epn2^tm1Ocr	MGI:4356021
cx7	Epn1^tm1Ocr/Epn1^tm1Ocr Epn2^tm1Ocr/Epn2^tm1Ocr	B6.129X1-Epn1^tm1Ocr Epn2^tm1Ocr	MGI:4356019

Genotype
MGI:4356018

hm1

• Allelic Composition: Epn2^tm1Ocr/Epn2^tm1Ocr
• Genetic Background: B6.129X1-Epn2^tm1Ocr

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

normal phenotype

no abnormal phenotype detected ( J:151951 )

• viable and fertile with no gross abnormalities

Genotype
MGI:5477818

cn2

• Allelic Composition: Epn1^tm1.1Wami/Epn1^tm1.1Wami; Epn2^tm1Ocr/Epn2^tm1Ocr; Tg(Cdh5-cre/ERT2)CIVE23Mlia/0; Tg(TRAMP)8247Ng/0
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * C57BL/6J

Reduced tumor growth in Epn1^tm1.1Wami/Epn1^tm1.1Wami Epn2^tm1Ocr/Epn2^tm1Ocr Tg(Cdh5-cre/ERT2)CIVE23Mlia/0 Tg(TRAMP)8247Ng/0 mice

mortality/aging

increased tumor-free survival time ( J:193966 )

• tamoxifen-treated mice exhibit decreased mortality compared with Tg(TRAMP)8247Ng control mice

neoplasm

decreased tumor growth/size ( J:193966 )

• tamoxifen-treated mice develop smaller tumors compared with Tg(TRAMP)8247Ng control mice

Genotype
MGI:5477817

cn3

• Allelic Composition: Epn1^tm1.1Wami/Epn1^tm1.1Wami; Epn2^tm1Ocr/Epn2^tm1Ocr; Tg(Cdh5-cre/ERT2)CIVE23Mlia/0
• Genetic Background: involves: 129X1/SvJ * C57BL/6J

Disrupted endothelial junctions in tumor vessels of Epn1^tm1.1Wami/Epn1^tm1.1Wami Epn2^tm1Ocr/Epn2^tm1Ocr Tg(Cdh5-cre/ERT2)CIVE23Mlia/0 mice

mortality/aging

decreased susceptibility to induced morbidity/mortality ( J:193966 )

• tamoxifen-treated mice transplanted with GL261glioma cells survive longer than with control mice

neoplasm

abnormal tumor vascularization ( J:193966 )

• tamoxifen-treated mice transplanted with Lewis Lung carcinoma (LLC) cells exhibit disorganized, fragile, immature, enlarged and leaky tumor vessels compared with control mice

• however, treatment with a VEGFR2 kinase inhibitor restored tumor vasculature

decreased incidence of tumors by chemical induction ( J:193966 )

• tamoxifen-treated mice subjected to AOM/DSS exhibit reduced tumor incidence and decreased tumor growth compared with control mice

decreased tumor growth/size ( J:193966 )

• tamoxifen-treated mice transplanted with Lewis Lung carcinoma (LLC) cells develop fewer, smaller tumors that grow at a slower rate compared with control mice

• tamoxifen-treated mice transplanted with GL261glioma cells develop smaller tumors compared with control mice

• tamoxifen-treated mice subjected to AOM/DSS exhibit reduced tumor incidence and decreased tumor growth compared with control mice

cardiovascular system

abnormal tumor vascularization ( J:193966 )

• tamoxifen-treated mice transplanted with Lewis Lung carcinoma (LLC) cells exhibit disorganized, fragile, immature, enlarged and leaky tumor vessels compared with control mice

• however, treatment with a VEGFR2 kinase inhibitor restored tumor vasculature

abnormal vascular endothelial cell migration ( J:193966 )

• endothelial cells treated with tamoxifen exhibit enhanced VEGF-stimulated migration compared with control cells

abnormal vascular endothelial cell physiology ( J:193966 )

• endothelial cells treated with tamoxifen exhibit disrupted endothelial junctions compared with control cells

increased vascular endothelial cell proliferation ( J:193966 )

• endothelial cells treated with tamoxifen exhibit enhanced VEGF-stimulated proliferation compared with control cells

increased vascular permeability ( J:193966 )

• of tumor vasculature in tamoxifen-treated mice transplanted with Lewis Lung carcinoma (LLC) cells

• however, vascular permeability of blood vessels in major organs is normal

cellular

abnormal vascular endothelial cell migration ( J:193966 )

• endothelial cells treated with tamoxifen exhibit enhanced VEGF-stimulated migration compared with control cells

increased vascular endothelial cell proliferation ( J:193966 )

• endothelial cells treated with tamoxifen exhibit enhanced VEGF-stimulated proliferation compared with control cells

homeostasis/metabolism

decreased incidence of tumors by chemical induction ( J:193966 )

• tamoxifen-treated mice subjected to AOM/DSS exhibit reduced tumor incidence and decreased tumor growth compared with control mice

Genotype
MGI:5477819

cn4

• Allelic Composition: Epn1^tm1.1Wami/Epn1^tm1.1Wami; Epn2^tm1Ocr/Epn2^tm1Ocr; Tg(Cdh5-cre)7Mlia/0
• Genetic Background: involves: C57BL/6J * FVB/N

Reduced tumor growth in Epn1^tm1.1Wami/Epn1^tm1.1Wami Epn2^tm1Ocr/Epn2^tm1Ocr Tg(Cdh5-cre/ERT2)CIVE23Mlia/0 and Epn1^tm1.1Wami/Epn1^tm1.1Wami Epn2^tm1Ocr/Epn2^tm1Ocr Tg(Cdh5-cre)7Mlia/0 mice

neoplasm

decreased tumor growth/size ( J:193966 )

• mice transplanted with Lewis Lung carcinoma (LLC) cells develop fewer tumors that grow at a slower rate compared with control mice

Genotype
MGI:4356020

cx5

• Allelic Composition: Epn1^tm1Ocr/Epn1⁺; Epn2^tm1Ocr/Epn2^tm1Ocr
• Genetic Background: B6.129X1-Epn1^tm1Ocr Epn2^tm1Ocr

mortality/aging

decreased survivor rate ( J:151951 )

• not as severe as in mice heterozygous for the Epn2 mutation and homozygous for the Epn1 mutation

premature death ( J:151951 )

• not as severe as in mice heterozygous for the Epn2 mutation and homozygous for the Epn1 mutation

growth/size/body

slow postnatal weight gain ( J:151951 )

• not as severe as in mice heterozygous for the Epn2 mutation and homozygous for the Epn1 mutation

Genotype
MGI:4356021

cx6

• Allelic Composition: Epn1^tm1Ocr/Epn1^tm1Ocr; Epn2^tm1Ocr/Epn2⁺
• Genetic Background: B6.129X1-Epn1^tm1Ocr Epn2^tm1Ocr

mortality/aging

decreased survivor rate ( J:151951 )

premature death ( J:151951 )

• percentage of mice surviving to 10 months of age is reduced

growth/size/body

slow postnatal weight gain ( J:151951 )

reproductive system

reduced fertility ( J:151951 )

Genotype
MGI:4356019

cx7

• Allelic Composition: Epn1^tm1Ocr/Epn1^tm1Ocr; Epn2^tm1Ocr/Epn2^tm1Ocr
• Genetic Background: B6.129X1-Epn1^tm1Ocr Epn2^tm1Ocr

Major developmental defects in Epn1^tm1Ocr/Epn1^tm1Ocr Epn2^tm1Ocr/Epn2^tm1Ocr embryos

mortality/aging

embryonic lethality during organogenesis, complete penetrance ( J:151951 )

• die between E9.5 and E11.5

embryo

abnormal embryo turning ( J:151951 )

• fail to undergo axial rotation in the sagital plane

embryonic growth arrest ( J:151951 )

• arrest by E9.5

decreased embryo size ( J:151951 )

• at E9.0

abnormal neural tube morphology ( J:151951 )

• at E9.0 picnotic cells are seen in the neural tube

open neural tube ( J:151951 )

• at E9.0

abnormal somite development ( J:151951 )

abnormal somite shape ( J:151951 )

• somites that do form are irregular in size and shape

abnormal somite size ( J:151951 )

• somites that do form are irregular in size and shape

incomplete somite formation ( J:151951 )

• severely impaired somitogenesis resulting in a reduction in the number of somites formed by E9.5

absent placental labyrinth ( J:151951 )

• at E9.0

abnormal vitelline vascular remodeling ( J:151951 )

• lack large vitelline vessels and the sinusoids are larger and dilated at E9.0 indicating failure to remodel the vascular plexus

nervous system

abnormal brain vasculature morphology ( J:151951 )

• at E9.0, vessels in the telencephalic region fail to form finely branched trees, instead a coarse network of uniformly sized vessels is present

abnormal neural tube morphology ( J:151951 )

• at E9.0 picnotic cells are seen in the neural tube

open neural tube ( J:151951 )

• at E9.0

cardiovascular system

abnormal blood vessel morphology ( J:151951 )

• at E9.0 in the intersomitic region, vessels are only present in areas where somites develop and these vessels are disorganized compared to controls

abnormal brain vasculature morphology ( J:151951 )

• at E9.0, vessels in the telencephalic region fail to form finely branched trees, instead a coarse network of uniformly sized vessels is present

abnormal developmental vascular remodeling ( J:151951 )

• defects in angiogenic vascular remodeling

thin ventricular wall ( J:151951 )

• atrophic ventricular wall seen at E9.5

cellular

cellular phenotype ( J:151951 )

N • no defects in proliferation or clathrin mediated endocytosis are detected in MEFs in contrast results from previous experiments using Epn1 knockdown cells

growth/size/body

decreased embryo size ( J:151951 )

• at E9.0